Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma

Gene Therapy volume 13, pages 1263–1271 (2006)Cite this article

Abstract

MIG (monokine induced by interferon-γ) is a CXC chemokine ligand (CXCL9) that can potently inhibit angiogenesis, and displays thymus-dependent antitumor effects. The effectiveness of a treatment combining gene therapy with plasmid-borne MIG (pORF-MIG) and low-dose cisplatin chemotherapy was determined using colon carcinoma (CT26) and Lewis lung carcinoma (LL/2c) murine models. The program was carried out via intramuscular delivery of pORF-MIG at 100 μg/mouse twice a week for 4 weeks, and/or intraperitoneal delivery of cisplatin at 0.6 mg/kg/mouse every 3 days for 48 days. Tumor volume and survival time were evaluated after treatment. CD31 immunohistochemical staining in tumor tissues and alginate capsule models in vivo was used to evaluate angiogenesis. Induction of apoptosis and cytotoxic T-lymphocyte (CTL) activity were also assessed. The combination of pORF-MIG and low-dose cisplatin produced significant antitumor activity, with complete tumor regression in 4/10 of CT26 colon carcinomas and 3/10 of LL/2c lung carcinomas, low vascularity, in alginate capsules, apparently degraded tumor microvessel density, and increased induction of apoptotic and CTL activities compared with either treatment alone. This study suggests that the combination of pORF-MIG plus cisplatin augments the inhibition of angiogenesis and the induction of apoptosis or CTL activity, all of which enhance antitumor activity. These findings may prove useful in further explorations of the application of combinatorial approaches to the treatment of solid tumors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Kerbel RS, Klement G, Pritchard KI, Kamen B . Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 2002; 13: 12–15.

    Article  CAS  Google Scholar 

  2. Kamen BA, Rubin E, Aisner J, Glatstein E . High-time chemotherapy or high time for low dose. J Clin Oncol 2000; 18: 2935–2937.

    Article  CAS  Google Scholar 

  3. Gasparini G . Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2001; 2: 733–740.

    Article  CAS  Google Scholar 

  4. Boehm T, Folkman J, Browder T, O'Reilly MS . Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404–407.

    Article  CAS  Google Scholar 

  5. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15–R24.

    Article  CAS  Google Scholar 

  6. Bocci G, Nicolaou KC, Kerbel RS . Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002; 62: 6938–6943.

    CAS  PubMed  Google Scholar 

  7. Kerbel RS . Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 1991; 13: 31–36.

    Article  CAS  Google Scholar 

  8. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878–1886.

    CAS  Google Scholar 

  9. Folkman J . Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757–1763.

    Article  CAS  Google Scholar 

  10. Harris AL . Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy. Recent Res Cancer Res 1998; 152: 341–352.

    Article  CAS  Google Scholar 

  11. Eckhardt SG, Pluda JM . Development of angiogenesis inhibitors for cancer therapy. Invest New Drug 1997; 15: 1–3.

    Article  CAS  Google Scholar 

  12. Folkman J . Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2003; 2: S127–S133.

    CAS  Google Scholar 

  13. Tandle A, Blazer DG, Libutti SK . Antiangiogenic gene therapy of cancer: recent developments. J Transl Med 2004; 2: 22.

    Article  Google Scholar 

  14. Rollins BJ . Chemokines. Blood 1997; 90: 909–928.

    CAS  Google Scholar 

  15. Rossi D, Zlotnik A . The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217–242.

    Article  CAS  Google Scholar 

  16. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995; 270: 27348–27357.

    Article  CAS  Google Scholar 

  17. Sgadari C, Farber JM, Angiolillo AL, Liao F, Teruya-Feldstein J, Burd PR et al. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo. Blood 1997; 89: 2635–2643.

    CAS  Google Scholar 

  18. Gasperini S, Marchi M, Calzetti F, Laudanna C, Vicentini L, Olsen H et al. Gene expression and production of the monokine induced by IFN-γ (MIG), IFN-inducible T cell-chemoattractant (I-TAC), and IFN-γ inducible protein-10(IP-10) chemokines by human neutrophils. J Immunol 1999; 162: 4928–4937.

    CAS  PubMed  Google Scholar 

  19. Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM . Human Mig chemokine: biochemical and functional characterization. J Exp Med 1995; 182: 1301–1314.

    Article  CAS  Google Scholar 

  20. Marx J . Angiogenesis: a boost for tumor starvation. Science 2003; 301: 452–454.

    Article  CAS  Google Scholar 

  21. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001; 61: 7669–7674.

    CAS  Google Scholar 

  22. Jin RJ, Kwak C, Lee SG, Lee CH, Soo CG, Park MS et al. The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts. Cancer Gene Ther 2000; 7: 1537–1542.

    Article  CAS  Google Scholar 

  23. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J . Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst 1995; 87: 581–586.

    Article  CAS  Google Scholar 

  24. Bikfalvi A, Gimenez-Gallego G . The control of angiogenesis and tumor invasion by platelet factor-4 and platelet factor-4-derived molecules. Semin Thromb Hemost 2004; 30: 137–144.

    Article  CAS  Google Scholar 

  25. Feldman AL, Friedl J, Lans TE, Libutti SK, Lorang D, Miller MS et al. Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer 2002; 99: 149–153.

    Article  CAS  Google Scholar 

  26. Addison CL, Arenberg DA, Morris SB, Xue YY, Burdick MD, Mulligan MS et al. The CXC chemokine, monokine induced by interferon-γ, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther 2000; 11: 247–261.

    Article  CAS  Google Scholar 

  27. Angiolillo AL, Sgadari C, Tosato G . A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann NY Acad Sci 1996; 795: 158–167.

    Article  CAS  Google Scholar 

  28. Soto H, Wang W, Strieter RM, Copeland NG, Gilbert DJ, Jenkins NA et al. The CC chemokine 6-Ckine binds the CXC chemokine receptor CXCR3. Proc Natl Acad Sci USA 1998; 95: 8205–8210.

    Article  CAS  Google Scholar 

  29. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I et al. Chemokine receptor specific for IP-10 and MIG: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184: 963–969.

    Article  CAS  Google Scholar 

  30. Farber JM . Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997; 61: 246–257.

    Article  CAS  Google Scholar 

  31. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 1388–1393.

    CAS  Google Scholar 

  32. Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F et al. Low-dose chemotherapy combined with an anti-angiogenic drug reduces human glioma growth in vivo. Cancer Res 2001; 61: 7501–7506.

    CAS  Google Scholar 

  33. Hou JM, Liu JY, Yang L, Zhao X, Tian L, Ding ZY et al. Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities. Oncology 2005; 69: 81–87.

    Article  CAS  Google Scholar 

  34. Folkman J . Angiogenesis and apoptosis. Semin Cancer Biol 2003; 13: 159–167.

    Article  CAS  Google Scholar 

  35. Yao B, He QM, Tian L, Xiao F, Jiang Y, Zhang R et al. Enhanced antitumor effect of the combination of tumstatin gene therapy and gemcitabine in murine models. Hum Gene Ther 2005; 16: 1075–1086.

    Article  CAS  Google Scholar 

  36. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R et al. Expression of the angiogenic factors vascular endothelial growth factor, acidic and basic fibroblast growth factor, tumor growth factor-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963–969.

    CAS  Google Scholar 

  37. Ruehlmann JM, Xiang R, Niethammer AG, Ba Y, Pertl U, Dolman CS et al. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res 2001; 61: 8498–8503.

    CAS  PubMed  Google Scholar 

  38. Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V . Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 2003; 63: 8408–8413.

    CAS  PubMed  Google Scholar 

  39. Wei YQ, Huang MJ, Yang L, Zhao X, Tian L, Lu Y et al. Immunogene therapy of tumors with vaccine based on xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 2001; 98: 11545–11550.

    Article  CAS  Google Scholar 

  40. Xiao F, Wei Y, Yang L, Zhao X, Tian L, Ding Z et al. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Therapy 2002; 9: 1207–1213.

    Article  CAS  Google Scholar 

  41. McAllister F, Steele C, Zheng M, Young E, Shellito JE, Marrero L et al. T cytotoxic-1 CD8+ T Cells are effector cells against pneumocystis in mice. J Immunol 2004; 172: 1132–1138.

    Article  CAS  Google Scholar 

  42. Tan GH, Tian L, Wei YQ, Zhao X, Li J, Wu Y et al. Combinaton of low-dose cisplatin and recombination xenogeheic endoglin as a vaccin induses synergistic antitumor activities. Int J Cancer 2004; 112: 701–706.

    Article  CAS  Google Scholar 

  43. Moorsel CJ, Pinedo HM, Smid K, Comijn EM, Voorn DA, Veerman G et al. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. Eur J Cancer 2000; 36: 2420–2429.

    Article  Google Scholar 

  44. He QM, Wei YQ, Tian L, Zhao X, Su JM, Yang L et al. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem 2003; 278: 21831–21836.

    Article  CAS  Google Scholar 

  45. Hoffmann J, Schirner M, Menrad A, Schneider MR . A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Res 1997; 57: 3847–3851.

    CAS  Google Scholar 

  46. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6: 1160–1166.

    Article  CAS  Google Scholar 

  47. Wild R, Ramakrishnan S, Sedgewick J, Griffioen AW . Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density. Microvasc Res 2000; 59: 368–376.

    Article  CAS  Google Scholar 

  48. Fields RC, Shimizu K, Mule JJ . Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 9482–9487.

    Article  CAS  Google Scholar 

  49. Lu Y, Wei YQ, Tian L, Zhao X, Yang L, Hu B et al. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor1. J Immunol 2003; 170: 3162–3170.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was sponsored by grants from National Key Basic Research Program of China (2004CB518800 and 2001CB510001), Project of National Natural Science Foundation of China, National 863 projects.

Author information

Authors and Affiliations

  1. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China

    R Zhang, L Tian, L-J Chen, F Xiao, J-M Hou, G Li, B Yao, Y-J Wen, J Li, L Zhang, X-C Chen, F Luo, F Peng, Y Jiang & Y-Q Wei

  2. Cancer Center, Chengdu Military General Hospital, Chengdu, China

    R Zhang

  3. Department of Gynecology and Obstetrics, Second West China Hospital, West China Medical School, Sichuan University, Chengdu, China

    X Zhao

Authors
  1. R Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L-J Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J-M Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. X Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y-J Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. L Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. X-C Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. F Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. F Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Y Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Y-Q Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y-Q Wei.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, R., Tian, L., Chen, LJ. et al. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma. Gene Ther 13, 1263–1271 (2006). https://doi.org/10.1038/sj.gt.3302756

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302756

Keywords

This article is cited by

Search

Advanced search

Quick links